| ■ 영문 제목 : Global JAK Inhibitor Based Cancer Drug Market Growth 2021-2026 | |
 | ■ 상품코드 : LPI-2201K00078 ■ 조사/발행회사 : LP Information ■ 발행일 : 2021년 12월 (※2025년 최신판이 있습니다. 문의 주세요.) ■ 페이지수 : 80 ■ 작성언어 : 영어 ■ 보고서 형태 : PDF ■ 납품 방식 : E메일 ■ 조사대상 지역 : 글로벌 ■ 산업 분야 : 의료, 제약 |
| Single User (1명 열람용) | USD3,660 ⇒환산￦4,941,000 | 견적의뢰/주문/질문 |
| Multi User (5명 열람용) | USD5,490 ⇒환산￦7,411,500 | 견적의뢰/주문/질문 |
| Corporate User (동일기업내 공유가능) | USD7,320 ⇒환산￦9,882,000 | 견적의뢰/구입/질문 |
|
※가격옵션 설명 - 납기는 즉일~2일소요됩니다. 3일이상 소요되는 경우는 별도표기 또는 연락드립니다. - 지불방법은 계좌이체/무통장입금 또는 카드결제입니다. |
| 본 조사보고서는 JAK 억제제 베이스 항암제의 세계시장에 관해서 조사, 분석한 자료로서, 기업별 시장 점유율, 지역별 시장규모 (미주, 미국, 캐나다, 멕시코, 브라질, 아시아, 중국, 일본, 한국, 동남아시아, 인도, 유럽, 독일, 프랑스, 영국, 이탈리아, 러시아, 중동/아프리카, 이집트, 남아프리카, 터키, 중동GCC국 등), 시장동향, 판매/유통업자/고객 리스트, 시장예측 (2021년-2026년), 주요 기업동향 (기업정보, 제품, 판매량, 매출, 가격, 매출총이익) 등의 정보를 포함하고 있습니다. 또한, 주요지역의 종류별 시장규모 (토파시티닙, 루키소리티닙, 바리시티닙)와 용도별 시장규모 (류마티스 관절염 (RA), 진성 다혈증 (PCV), 골수 섬유증 (MF)) 데이터도 수록되어 있습니다. - 조사 범위 - 경영자용 요약 - 기업별 JAK 억제제 베이스 항암제 시장 점유율 - 지역별 JAK 억제제 베이스 항암제 시장규모 - 주요지역의 종류별 시장규모 (토파시티닙, 루키소리티닙, 바리시티닙) - 주요지역의 용도별 시장규모 (류마티스 관절염 (RA), 진성 다혈증 (PCV), 골수 섬유증 (MF)) - 미주의 JAK 억제제 베이스 항암제 시장규모 (미국, 캐나다, 멕시코, 브라질 등) - 아시아의 JAK 억제제 베이스 항암제 시장규모 (중국, 일본, 한국, 동남아시아, 인도 등) - 유럽의 JAK 억제제 베이스 항암제 시장규모 (독일, 프랑스, 영국, 이탈리아, 러시아 등) - 중동/아프리카의 JAK 억제제 베이스 항암제 시장규모 (이집트, 남아프리카, 터키, 중동GCC지역 등) - 시장의 성장요인, 과제, 동향 - 마케팅, 유통업자, 고객리스트 - 세계의 JAK 억제제 베이스 항암제 시장예측 (2021년-2026년) - 주요 기업동향 (기업정보, 제품, 판매량, 매출, 가격, 매출총이익) Pfizer, Incyte, Novartis, Eli Lilly - 조사의 결과/결론 |
According to this latest study, the 2021 growth of JAK Inhibitor Based Cancer Drug will have significant change from previous year. By the most conservative estimates of global JAK Inhibitor Based Cancer Drug market size (most likely outcome) will be a year-over-year revenue growth rate of XX% in 2021, from US$ xx million in 2020. Over the next five years the JAK Inhibitor Based Cancer Drug market will register a xx% CAGR in terms of revenue, the global market size will reach US$ xx million by 2026.
This report presents a comprehensive overview, market shares, and growth opportunities of JAK Inhibitor Based Cancer Drug market by product type, application, key manufacturers and key regions and countries.
Segmentation by type: breakdown data from 2016 to 2021, in Section 2.3; and forecast to 2026 in section 11.7.
Tofacitinib
Ruxolitinib
Baricitinib
Segmentation by application: breakdown data from 2016 to 2021, in Section 2.4; and forecast to 2026 in section 11.8.
Rheumatoid Arthritis (RA)
Polycythemia Vera (PCV)
Myelofibrosis (MF)
This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The report also presents the market competition landscape and a corresponding detailed analysis of the major vendor/manufacturers in the market. The key manufacturers covered in this report: Breakdown data in Chapter 3.
Pfizer
Incyte
Novartis
Eli Lilly
1 Scope of the Report 2 Executive Summary 3 Global JAK Inhibitor Based Cancer Drug by Company 4 JAK Inhibitor Based Cancer Drug by Region 5 Americas 6 APAC 7 Europe 8 Middle East & Africa 9 Market Drivers, Challenges and Trends 10 Marketing, Distributors and Customer 11 Global JAK Inhibitor Based Cancer Drug Market Forecast 12 Key Players Analysis 13 Research Findings and Conclusion List of TablesTable 1. JAK Inhibitor Based Cancer Drug Consumption CAGR by Region (2020-2026) & ($ Millions) Table 2. Major Players of Tofacitinib Table 3. Major Players of Ruxolitinib Table 4. Major Players of Baricitinib Table 5. Global JAK Inhibitor Based Cancer Drug Sales by Type (2016-2021) & (K Units) Table 6. Global JAK Inhibitor Based Cancer Drug Sales Market Share by Type (2016-2021) Table 7. Global JAK Inhibitor Based Cancer Drug Revenue by Type (2016-2021) & ($ million) Table 8. Global JAK Inhibitor Based Cancer Drug Revenue Market Share by Type (2016-2021) Table 9. Global JAK Inhibitor Based Cancer Drug Sale Price by Type (2016-2021) Table 10. Global JAK Inhibitor Based Cancer Drug Sales by Application (2016-2021) & (K Units) Table 11. Global JAK Inhibitor Based Cancer Drug Sales Market Share by Application (2016-2021) Table 12. Global JAK Inhibitor Based Cancer Drug Value by Application (2016-2021) Table 13. Global JAK Inhibitor Based Cancer Drug Revenue Market Share by Application (2016-2021) Table 14. Global JAK Inhibitor Based Cancer Drug Sale Price by Application (2016-2021) Table 15. Global JAK Inhibitor Based Cancer Drug Sales by Company (2019-2021) & (K Units) Table 16. Global JAK Inhibitor Based Cancer Drug Sales Market Share by Company (2019-2021) Table 17. Global JAK Inhibitor Based Cancer Drug Revenue by Company (2019-2021) ($ Millions) Table 18. Global JAK Inhibitor Based Cancer Drug Revenue Market Share by Company (2019-2021) Table 19. Global JAK Inhibitor Based Cancer Drug Sale Price by Company (2019-2021) Table 20. Key Manufacturers JAK Inhibitor Based Cancer Drug Producing Area Distribution and Sales Area Table 21. Players JAK Inhibitor Based Cancer Drug Products Offered Table 22. JAK Inhibitor Based Cancer Drug Concentration Ratio (CR3, CR5 and CR10) & (2019-2021) Table 23. New Products and Potential Entrants Table 24. Mergers & Acquisitions, Expansion Table 25. Global JAK Inhibitor Based Cancer Drug Sales by Region (2016-2021) (K Units) Table 26. Global JAK Inhibitor Based Cancer Drug Sales Market Share by Region (2016-2021) Table 27. Global JAK Inhibitor Based Cancer Drug Revenue by Region (2016-2021) & ($ Millions) Table 28. Global JAK Inhibitor Based Cancer Drug Revenue Market Share by Region (2016-2021) Table 29. Americas JAK Inhibitor Based Cancer Drug Sales by Country (2016-2021) & (K Units) Table 30. Americas JAK Inhibitor Based Cancer Drug Sales Market Share by Country (2016-2021) Table 31. Americas JAK Inhibitor Based Cancer Drug Revenue by Country (2016-2021) & ($ Millions) Table 32. Americas JAK Inhibitor Based Cancer Drug Revenue Market Share by Country (2016-2021) Table 33. Americas JAK Inhibitor Based Cancer Drug Sales by Type (2016-2021) & (K Units) Table 34. Americas JAK Inhibitor Based Cancer Drug Sales Market Share by Type (2016-2021) Table 35. Americas JAK Inhibitor Based Cancer Drug Sales by Application (2016-2021) & (K Units) Table 36. Americas JAK Inhibitor Based Cancer Drug Sales Market Share by Application (2016-2021) Table 37. APAC JAK Inhibitor Based Cancer Drug Sales by Region (2016-2021) & (K Units) Table 38. APAC JAK Inhibitor Based Cancer Drug Sales Market Share by Region (2016-2021) Table 39. APAC JAK Inhibitor Based Cancer Drug Revenue by Region (2016-2021) & ($ Millions) Table 40. APAC JAK Inhibitor Based Cancer Drug Revenue Market Share by Region (2016-2021) Table 41. APAC JAK Inhibitor Based Cancer Drug Sales by Type (2016-2021) & (K Units) Table 42. APAC JAK Inhibitor Based Cancer Drug Sales Market Share by Type (2016-2021) Table 43. APAC JAK Inhibitor Based Cancer Drug Sales by Application (2016-2021) & (K Units) Table 44. APAC JAK Inhibitor Based Cancer Drug Sales Market Share by Application (2016-2021) Table 45. Europe JAK Inhibitor Based Cancer Drug Sales by Country (2016-2021) & (K Units) Table 46. Europe JAK Inhibitor Based Cancer Drug Sales Market Share by Country (2016-2021) Table 47. Europe JAK Inhibitor Based Cancer Drug Revenue by Country (2016-2021) & ($ Millions) Table 48. Europe JAK Inhibitor Based Cancer Drug Revenue Market Share by Country (2016-2021) Table 49. Europe JAK Inhibitor Based Cancer Drug Sales by Type (2016-2021) & (K Units) Table 50. Europe JAK Inhibitor Based Cancer Drug Sales Market Share by Type (2016-2021) Table 51. Europe JAK Inhibitor Based Cancer Drug Sales by Application (2016-2021) & (K Units) Table 52. Europe JAK Inhibitor Based Cancer Drug Sales Market Share by Application (2016-2021) Table 53. Middle East & Africa JAK Inhibitor Based Cancer Drug Sales by Country (2016-2021) & (K Units) Table 54. Middle East & Africa JAK Inhibitor Based Cancer Drug Sales Market Share by Country (2016-2021) Table 55. Middle East & Africa JAK Inhibitor Based Cancer Drug Revenue by Country (2016-2021) & ($ Millions) Table 56. Middle East & Africa JAK Inhibitor Based Cancer Drug Revenue Market Share by Country (2016-2021) Table 57. Middle East & Africa JAK Inhibitor Based Cancer Drug Sales by Type (2016-2021) & (K Units) Table 58. Middle East & Africa JAK Inhibitor Based Cancer Drug Sales Market Share by Type (2016-2021) Table 59. Middle East & Africa JAK Inhibitor Based Cancer Drug Sales by Application (2016-2021) & (K Units) Table 60. Middle East & Africa JAK Inhibitor Based Cancer Drug Sales Market Share by Application (2016-2021) Table 61. Key and Potential Regions of JAK Inhibitor Based Cancer Drug Table 62. Key Application and Potential Industries of JAK Inhibitor Based Cancer Drug Table 63. Key Challenges of JAK Inhibitor Based Cancer Drug Table 64. Key Trends of JAK Inhibitor Based Cancer Drug Table 65. JAK Inhibitor Based Cancer Drug Distributors List Table 66. JAK Inhibitor Based Cancer Drug Customer List Table 67. Global JAK Inhibitor Based Cancer Drug Sales Forecast by Region (2021-2026) & (K Units) Table 68. Global JAK Inhibitor Based Cancer Drug Consumption Market Forecast by Region Table 69. Global JAK Inhibitor Based Cancer Drug Revenue Forecast by Region (2021-2026) & ($ millions) Table 70. Global JAK Inhibitor Based Cancer Drug Revenue Market Share Forecast by Region (2021-2026) Table 71. Americas JAK Inhibitor Based Cancer Drug Sales Forecast by Country (2021-2026) & (K Units) Table 72. Americas JAK Inhibitor Based Cancer Drug Revenue Forecast by Country (2021-2026) & ($ millions) Table 73. APAC JAK Inhibitor Based Cancer Drug Sales Forecast by Region (2021-2026) & (K Units) Table 74. APAC JAK Inhibitor Based Cancer Drug Revenue Forecast by Region (2021-2026) & ($ millions) Table 75. Europe JAK Inhibitor Based Cancer Drug Sales Forecast by Country (2021-2026) & (K Units) Table 76. Europe JAK Inhibitor Based Cancer Drug Revenue Forecast by Country (2021-2026) & ($ millions) Table 77. Middle East & Africa JAK Inhibitor Based Cancer Drug Sales Forecast by Country (2021-2026) & (K Units) Table 78. Middle East & Africa JAK Inhibitor Based Cancer Drug Revenue Forecast by Country (2021-2026) & ($ millions) Table 79. Global JAK Inhibitor Based Cancer Drug Sales Forecast by Type (2021-2026) & (K Units) Table 80. Global JAK Inhibitor Based Cancer Drug Sales Market Share Forecast by Type (2021-2026) Table 81. Global JAK Inhibitor Based Cancer Drug Revenue Forecast by Type (2021-2026) & ($ Millions) Table 82. Global JAK Inhibitor Based Cancer Drug Revenue Market Share Forecast by Type (2021-2026) Table 83. Global JAK Inhibitor Based Cancer Drug Sales Forecast by Application (2021-2026) & (K Units) Table 84. Global JAK Inhibitor Based Cancer Drug Sales Market Share Forecast by Application (2021-2026) Table 85. Global JAK Inhibitor Based Cancer Drug Revenue Forecast by Application (2021-2026) & ($ Millions) Table 86. Global JAK Inhibitor Based Cancer Drug Revenue Market Share Forecast by Application (2021-2026) Table 87. Pfizer Basic Information, JAK Inhibitor Based Cancer Drug Manufacturing Base, Sales Area and Its Competitors Table 88. Pfizer JAK Inhibitor Based Cancer Drug Product Offered Table 89. Pfizer JAK Inhibitor Based Cancer Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2021E) Table 90. Pfizer Main Business Table 91. Pfizer Latest Developments Table 92. Incyte Basic Information, JAK Inhibitor Based Cancer Drug Manufacturing Base, Sales Area and Its Competitors Table 93. Incyte JAK Inhibitor Based Cancer Drug Product Offered Table 94. Incyte JAK Inhibitor Based Cancer Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2021E) Table 95. Incyte Main Business Table 96. Incyte Latest Developments Table 97. Novartis Basic Information, JAK Inhibitor Based Cancer Drug Manufacturing Base, Sales Area and Its Competitors Table 98. Novartis JAK Inhibitor Based Cancer Drug Product Offered Table 99. Novartis JAK Inhibitor Based Cancer Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2021E) Table 100. Novartis Main Business Table 101. Novartis Latest Developments Table 102. Eli Lilly Basic Information, JAK Inhibitor Based Cancer Drug Manufacturing Base, Sales Area and Its Competitors Table 103. Eli Lilly JAK Inhibitor Based Cancer Drug Product Offered Table 104. Eli Lilly JAK Inhibitor Based Cancer Drug Sales (K Units), Revenue ($ Million), Price (US$/Unit) and Gross Margin (2019-2021E) Table 105. Eli Lilly Main Business Table 106. Eli Lilly Latest Developments List of Figures Figure 1. Picture of JAK Inhibitor Based Cancer Drug Figure 2. JAK Inhibitor Based Cancer Drug Report Years Considered Figure 3. Research Objectives Figure 4. Research Methodology Figure 5. Research Process and Data Source Figure 6. Global JAK Inhibitor Based Cancer Drug Sales Growth Rate 2016-2026 (K Units) Figure 7. Global JAK Inhibitor Based Cancer Drug Revenue Growth Rate 2016-2026 ($ Millions) Figure 8. JAK Inhibitor Based Cancer Drug Sales by Region (2021 & 2026) & ($ millions) Figure 9. Product Picture of Tofacitinib Figure 10. Product Picture of Ruxolitinib Figure 11. Product Picture of Baricitinib Figure 12. Global JAK Inhibitor Based Cancer Drug Sales Market Share by Type in 2020 Figure 13. Global JAK Inhibitor Based Cancer Drug Revenue Market Share by Type (2016-2021) Figure 14. JAK Inhibitor Based Cancer Drug Consumed in Rheumatoid Arthritis (RA) Figure 15. Global JAK Inhibitor Based Cancer Drug Market: Rheumatoid Arthritis (RA) (2016-2021) & (K Units) Figure 16. JAK Inhibitor Based Cancer Drug Consumed in Polycythemia Vera (PCV) Figure 17. Global JAK Inhibitor Based Cancer Drug Market: Polycythemia Vera (PCV) (2016-2021) & (K Units) Figure 18. JAK Inhibitor Based Cancer Drug Consumed in Myelofibrosis (MF) Figure 19. Global JAK Inhibitor Based Cancer Drug Market: Myelofibrosis (MF) (2016-2021) & (K Units) Figure 20. Global JAK Inhibitor Based Cancer Drug Sales Market Share by Application (2016-2021) Figure 21. Global JAK Inhibitor Based Cancer Drug Revenue Market Share by Application in 2020 Figure 22. JAK Inhibitor Based Cancer Drug Revenue Market by Company in 2020 ($ Million) Figure 23. Global JAK Inhibitor Based Cancer Drug Revenue Market Share by Company in 2020 Figure 24. Global JAK Inhibitor Based Cancer Drug Sales Market Share by Regions (2016-2021) Figure 25. Global JAK Inhibitor Based Cancer Drug Revenue Market Share by Region in 2020 Figure 26. Americas JAK Inhibitor Based Cancer Drug Sales 2016-2021 (K Units) Figure 27. Americas JAK Inhibitor Based Cancer Drug Revenue 2016-2021 ($ Millions) Figure 28. APAC JAK Inhibitor Based Cancer Drug Sales 2016-2021 (K Units) Figure 29. APAC JAK Inhibitor Based Cancer Drug Revenue 2016-2021 ($ Millions) Figure 30. Europe JAK Inhibitor Based Cancer Drug Sales 2016-2021 (K Units) Figure 31. Europe JAK Inhibitor Based Cancer Drug Revenue 2016-2021 ($ Millions) Figure 32. Middle East & Africa JAK Inhibitor Based Cancer Drug Sales 2016-2021 (K Units) Figure 33. Middle East & Africa JAK Inhibitor Based Cancer Drug Revenue 2016-2021 ($ Millions) Figure 34. Americas JAK Inhibitor Based Cancer Drug Sales Market Share by Country in 2020 Figure 35. Americas JAK Inhibitor Based Cancer Drug Revenue Market Share by Country in 2020 Figure 36. Americas JAK Inhibitor Based Cancer Drug Sales Market Share by Type in 2020 Figure 37. Americas JAK Inhibitor Based Cancer Drug Sales Market Share by Application in 2020 Figure 38. United States JAK Inhibitor Based Cancer Drug Revenue Growth 2016-2021 ($ Millions) Figure 39. Canada JAK Inhibitor Based Cancer Drug Revenue Growth 2016-2021 ($ Millions) Figure 40. Mexico JAK Inhibitor Based Cancer Drug Revenue Growth 2016-2021 ($ Millions) Figure 41. Brazil JAK Inhibitor Based Cancer Drug Revenue Growth 2016-2021 ($ Millions) Figure 42. APAC JAK Inhibitor Based Cancer Drug Sales Market Share by Region in 2020 Figure 43. APAC JAK Inhibitor Based Cancer Drug Revenue Market Share by Regions in 2020 Figure 44. APAC JAK Inhibitor Based Cancer Drug Sales Market Share by Type in 2020 Figure 45. APAC JAK Inhibitor Based Cancer Drug Sales Market Share by Application in 2020 Figure 46. China JAK Inhibitor Based Cancer Drug Revenue Growth 2016-2021 ($ Millions) Figure 47. Japan JAK Inhibitor Based Cancer Drug Revenue Growth 2016-2021 ($ Millions) Figure 48. Korea JAK Inhibitor Based Cancer Drug Revenue Growth 2016-2021 ($ Millions) Figure 49. Southeast Asia JAK Inhibitor Based Cancer Drug Revenue Growth 2016-2021 ($ Millions) Figure 50. India JAK Inhibitor Based Cancer Drug Revenue Growth 2016-2021 ($ Millions) Figure 51. Australia JAK Inhibitor Based Cancer Drug Revenue Growth 2016-2021 ($ Millions) Figure 52. Europe JAK Inhibitor Based Cancer Drug Sales Market Share by Country in 2020 Figure 53. Europe JAK Inhibitor Based Cancer Drug Revenue Market Share by Country in 2020 Figure 54. Europe JAK Inhibitor Based Cancer Drug Sales Market Share by Type in 2020 Figure 55. Europe JAK Inhibitor Based Cancer Drug Sales Market Share by Application in 2020 Figure 56. Germany JAK Inhibitor Based Cancer Drug Revenue Growth 2016-2021 ($ Millions) Figure 57. France JAK Inhibitor Based Cancer Drug Revenue Growth 2016-2021 ($ Millions) Figure 58. UK JAK Inhibitor Based Cancer Drug Revenue Growth 2016-2021 ($ Millions) Figure 59. Italy JAK Inhibitor Based Cancer Drug Revenue Growth 2016-2021 ($ Millions) Figure 60. Russia JAK Inhibitor Based Cancer Drug Revenue Growth 2016-2021 ($ Millions) Figure 61. Middle East & Africa JAK Inhibitor Based Cancer Drug Sales Market Share by Country in 2020 Figure 62. Middle East & Africa JAK Inhibitor Based Cancer Drug Revenue Market Share by Country in 2020 Figure 63. Middle East & Africa JAK Inhibitor Based Cancer Drug Sales Market Share by Type in 2020 Figure 64. Middle East & Africa JAK Inhibitor Based Cancer Drug Sales Market Share by Application in 2020 Figure 65. Egypt JAK Inhibitor Based Cancer Drug Revenue Growth 2016-2021 ($ Millions) Figure 66. South Africa JAK Inhibitor Based Cancer Drug Revenue Growth 2016-2021 ($ Millions) Figure 67. Israel JAK Inhibitor Based Cancer Drug Revenue Growth 2016-2021 ($ Millions) Figure 68. Turkey JAK Inhibitor Based Cancer Drug Revenue Growth 2016-2021 ($ Millions) Figure 69. GCC Country JAK Inhibitor Based Cancer Drug Revenue Growth 2016-2021 ($ Millions) Figure 70. Channels of Distribution Figure 71. Distributors Profiles |
| ※본 조사보고서 [세계의 JAK 억제제 베이스 항암제 시장예측 2021년-2026년] (코드 : LPI-2201K00078) 판매에 관한 면책사항을 반드시 확인하세요. |
| ※본 조사보고서 [세계의 JAK 억제제 베이스 항암제 시장예측 2021년-2026년] 에 대해서 E메일 문의는 여기를 클릭하세요. |